Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in Patients With Non-Muscle Invasive Bladder Cancer and Previous Failure of Conventional BCG Therapy
ContributorsRentsch, Cyrill A; Bosshard, Piet; Mayor, Grégoire; Rieken, Malte; Püschel, Heike; Wirth, Grégory Johann; Cathomas, Richard; Parzmair, Gerald P; Grode, Leander; Eisele, Bernd; Sharma, Hitt; Gupta, Manish; Gairola, Sunil; Shaligram, Umesh; Goldenberger, Daniel; Spertini, François; Audran, Régine; Enoiu, Milica; Berardi, Simona; Hayoz, Stefanie; Wicki, Andreas
Published inOncoImmunology, vol. 9, no. 1, 1748981
Publication date2020
Abstract
Keywords
- BCG-failure
- GMO (genetically modified organism)
- NMIBC (Non-muscle-invasive bladder cancer)
- Clinical trial
- Listeriolysin
Affiliation
Research group
Funding
- Autre - Swiss Cancer Research Foundation (SCS); Swiss Cancer League (SCL)
Citation (ISO format)
RENTSCH, Cyrill A et al. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in Patients With Non-Muscle Invasive Bladder Cancer and Previous Failure of Conventional BCG Therapy. In: OncoImmunology, 2020, vol. 9, n° 1, p. 1748981. doi: 10.1080/2162402X.2020.1748981
Main files (1)
Article (Published version)
Identifiers
- PID : unige:136297
- DOI : 10.1080/2162402X.2020.1748981
- PMID : 32363120
Commercial URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
ISSN of the journal2162-4011